320 related articles for article (PubMed ID: 19519381)
21. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
22. Chemistry strategies in early drug discovery: an overview of recent trends.
Colombo M; Peretto I
Drug Discov Today; 2008 Aug; 13(15-16):677-84. PubMed ID: 18675762
[TBL] [Abstract][Full Text] [Related]
23. Preparative Scale Resolution of Enantiomers Enables Accelerated Drug Discovery and Development.
Leek H; Andersson S
Molecules; 2017 Jan; 22(1):. PubMed ID: 28106796
[TBL] [Abstract][Full Text] [Related]
24. [Separation of chiral pharmaceutical drugs by chromatographic and electrophoretic techniques].
Morin P
Ann Pharm Fr; 2009 Jul; 67(4):241-50. PubMed ID: 19596097
[TBL] [Abstract][Full Text] [Related]
25. Drug Stereochemistry: A Prodigy For Pharmacology and Drug Development.
Gandhi K; Shah U; Patel S
Curr Drug Discov Technol; 2020; 17(5):565-573. PubMed ID: 31057115
[TBL] [Abstract][Full Text] [Related]
26. Putting chirality to work: the strategy of chiral switches.
Agranat I; Caner H; Caldwell J
Nat Rev Drug Discov; 2002 Oct; 1(10):753-68. PubMed ID: 12360254
[TBL] [Abstract][Full Text] [Related]
27. Three-dimensional view of pharmacology.
Wainer IW
Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S4-8. PubMed ID: 1530004
[TBL] [Abstract][Full Text] [Related]
28. Asymmetric syntheses and transformations--tools for chirality multiplication in drug synthesis.
Gawroński J
Acta Pol Pharm; 2006; 63(5):333-51. PubMed ID: 17357583
[TBL] [Abstract][Full Text] [Related]
29. The cost benefit ratio of enantiomeric drugs.
Pifferi G; Perucca E
Eur J Drug Metab Pharmacokinet; 1995; 20(1):15-25. PubMed ID: 7588989
[TBL] [Abstract][Full Text] [Related]
30. Numerical descriptors for the characterization of chiral compounds and their applications in modeling biological and toxicological activities.
Natarajan R; Basak SC
Curr Top Med Chem; 2011; 11(7):771-87. PubMed ID: 21291398
[TBL] [Abstract][Full Text] [Related]
31. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
32. Bioanalysis of chiral compounds during drug development using a tiered approach.
Jian W; Edom RW; Huang MQ; Weng N
Bioanalysis; 2014 Mar; 6(5):629-39. PubMed ID: 24620805
[TBL] [Abstract][Full Text] [Related]
33. Model of complex chiral drug metabolic systems and numerical simulation of the remaining chirality toward analysis of dynamical pharmacological activity.
Ogino Y; Asahi T
J Theor Biol; 2015 May; 373():117-31. PubMed ID: 25791284
[TBL] [Abstract][Full Text] [Related]
34. Achieving continuous manufacturing for final dosage formation: challenges and how to meet them. May 20-21, 2014 Continuous Manufacturing Symposium.
Byrn S; Futran M; Thomas H; Jayjock E; Maron N; Meyer RF; Myerson AS; Thien MP; Trout BL
J Pharm Sci; 2015 Mar; 104(3):792-802. PubMed ID: 25501530
[TBL] [Abstract][Full Text] [Related]
35. Chiral Switch: Between Therapeutical Benefit and Marketing Strategy.
Hancu G; Modroiu A
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215352
[TBL] [Abstract][Full Text] [Related]
36. Enantiomeric separation and determination of absolute stereochemistry of asymmetric molecules in drug discovery: building chiral technology toolboxes.
McConnell O; Bach A; Balibar C; Byrne N; Cai Y; Carter G; Chlenov M; Di L; Fan K; Goljer I; He Y; Herold D; Kagan M; Kerns E; Koehn F; Kraml C; Marathias V; Marquez B; McDonald L; Nogle L; Petucci C; Schlingmann G; Tawa G; Tischler M; Williamson RT; Sutherland A; Watts W; Young M; Zhang MY; Zhang Y; Zhou D; Ho D
Chirality; 2007 Sep; 19(9):658-82. PubMed ID: 17390370
[TBL] [Abstract][Full Text] [Related]
37. The strategy of enantiomer patents of drugs.
Agranat I; Wainschtein SR
Drug Discov Today; 2010 Mar; 15(5-6):163-70. PubMed ID: 20116449
[TBL] [Abstract][Full Text] [Related]
38. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
39. Chirality and its implications in transdermal drug development.
Reddy IK; Kommuru TR; Zaghloul AA; Khan MA
Crit Rev Ther Drug Carrier Syst; 2000; 17(4):285-325. PubMed ID: 10958245
[TBL] [Abstract][Full Text] [Related]
40. [Chiral compounds and their pharmacologic effects].
Slováková A; Hutt AJ
Ceska Slov Farm; 1999 May; 48(3):107-12. PubMed ID: 10422348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
